AntriaBio, Inc. — Form 10-Q Summary
Entity and period: The supplied filing is for AntriaBio, Inc., not Rezolute, Inc. It covers the fiscal quarter and six months ended December 31, 2013, and is unaudited. AntriaBio was a development-stage biotechnology company developing sustained-release diabetes treatments, with AB101, a potential once-weekly basal insulin injection, as its lead candidate.
Financial performance and position
- Revenue: None since inception. The company reported no revenue-generating operations.
- Net loss: $1.819 million for the quarter, versus $0.538 million in the comparable 2012 quarter; $2.638 million for the six months, versus $1.168 million. Six-month operating expenses were $1.351 million, up from $1.043 million.
- Key expense items: Six-month interest expense was $788,164 and derivative expense was $505,821. The loss also included $330,636 of stock-based compensation and $417,636 of amortization of debt discounts.
- Cash flow and liquidity: Cash used in operating activities was $361,602 for the six months, compared with $743,548 in 2012. Financing activities provided $1.513 million; cash at December 31 was $1.145 million, versus $527 at June 30.
- Balance sheet: Current assets were $1.859 million and current liabilities $6.543 million, producing a reported working-capital deficit of $4.683 million. Total assets were $2.146 million; stockholders’ deficit was $4.397 million.
- Debt: Convertible notes had $5.153 million principal outstanding and a $3.497 million net carrying amount after discounts. The company said $2.013 million of notes had matured and remained unpaid at December 31, accruing interest. A related-party note had $234,700 outstanding. The filing’s MD&A separately describes approximately $5.4 million of aggregate convertible and bridge-note principal, including financing through January 2014.
Changes, outlook, and risks
- Six-month net loss more than doubled year over year. Payroll expense increased, partly due to stock-based compensation; consulting and professional fees declined. The new derivative charge and debt-discount amortization materially affected reported losses.
- Management stated that available cash and expected operating cash flows would not fund operations for more than one year. The filing says these conditions raise substantial doubt about the company’s ability to continue as a going concern; continued operations depend on additional financing.
- After the quarter, on January 15, 2014, the company closed a bridge financing with gross proceeds of $2.703 million before costs. Management anticipated raising as much as $30 million to fund development, including up to $15 million in early 2014 and potentially another $15 million later in 2014 or the first half of 2015. These were plans, not assured funding.
- Management planned preclinical and clinical work on AB101 in Russia, with results expected by the end of 2014 and in the first half of 2015, and planned U.S. IND-enabling work and clinical studies thereafter. The company also planned to lease and equip a manufacturing facility. Timing and execution depend on financing, regulatory requirements, and study results.
- The PR Pharmaceuticals asset purchase includes up to $44 million of contingent payments tied to clinical, licensing, regulatory, and sales milestones. No milestone had occurred by the report date.
- Other notable matters: a one-for-six reverse stock split had been approved but awaited regulatory approvals. Management concluded disclosure controls were ineffective due to a material weakness involving lack of segregation of duties and a need for a stronger internal-control environment.
Most important facts to verify
- Confirm the issuer identity: the provided filing names AntriaBio, Inc.; the request metadata names Rezolute, Inc.
- Check the status, terms, and actual net proceeds of the January 2014 bridge financing and any subsequent fundraising.
- Verify the repayment, conversion, or continued overdue status of matured notes and the company’s ability to meet near-term obligations.
- Assess whether AB101 studies, manufacturing preparations, and regulatory plans progressed as projected, and whether contingent acquisition milestones were triggered.
- Review subsequent disclosures on the going-concern uncertainty, reverse stock split, and remediation of the reported material weakness.